IMCR ▲ +4.4% - Immunocore Holdings plc
$IMCR - Immunocore presents promising data from Phase 1/2 trial cohort evaluating brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma
06-NOV-2026 12:00 PM ET
Share this post
More filings for $IMCR
IMCR ▼ -1.3% - Immunocore Holdings plcNov 6, 2026IMCR ▼ -0.3% - Immunocore Holdings plcOct 29, 2026IMCR - Immunocore Holdings plc - SEC Filing Update (07-OCT-2026) | ThinkSabio - Stocks SimplifiedOct 7, 2026IMCR ▼ -0.1% - Immunocore Holdings plcSep 1, 2026IMCR - Immunocore Holdings plc - SEC Filing Update (13-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 13, 2026IMCR - Immunocore Holdings plc - SEC Filing Update (06-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 6, 2026
View full $IMCR filing history →💬 Comments
Loading comments…
Leave a comment